Peginterferon Lambda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peginterferon lambda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peginterferon Lambda Today - Breaking & Trending Today

Late-Stage Trial in Chronic Hepatitis D Discontinued Due to Safety Concerns

Several trial participants experienced concerning hepatobiliary events. ....

European Medicines Agency , Data Safety Monitoring Board , New England Journal , Discontinue Phase , Peginterferon Lambda , Chronic Hepatitis , Receives Complete Response Letter , Hepatitis Delta , Rare Disease , Chronic Hepatitis D , Safety Concerns ,

Eiger scraps phase III but delta force deploying in hepatitis

One hepatitis delta virus player (HDV) has dropped out after Eiger Biopharmaceuticals Inc.’s phase III effort with peginterferon lambda turned up safety issues, while others remain busy in a space highlighted during last November’s meeting of the American Association for the Study of Liver Diseases. Shares of Palo Alto, Calif.-based Eiger (NASDAQ:EIGR) closed Sept. 13 at 41 cents, down 28 cents, or 40.6%, on word that the company is stopping the Limt-2 study in patients with chronic HDV. ....

United States , Eiger Biopharmaceuticals Inc , Eiger Biopharmaceuticals , American Association , Palo Alto , Eiger Biopharmaceuticals Inc , Peginterferon Lambda , Hepatitis Delta Virus ,

Eiger Halts Phase 3 LIMT-2 Trial in Hepatitis D

The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV. ....

David Apelian , Eiger Biopharmaceuticals , Data Safety Monitoring Board , Durable Virologic Response , Discontinue Phase , Peginterferon Lambda , Chronic Hepatitis , Press Release , Metabolic Diseases , David Apelian Takes Helm , Chronic Hepatitis Delta Virus , Limt 2 , Hepatitis Delta , Phase 3 ,

Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket

Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company focused on rare metabolic diseases, Wednesday said it has decided to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta or CHD. ....

David Apelian , Eiger Biopharmaceuticals Inc , More Such Health News , Eiger Biopharmaceuticals , Data Safety Monitoring Board , Peginterferon Lambda , Iger Peginterferon Lambda , Iger To Discontinue , Hd Patient , Rare Metabolic ,

Eiger BioPharmaceuticals Makes Interim CEO Permanent, It Chalks Out Portfolio Prioritization Review, Layoffs - Eiger BioPharmaceuticals (NASDAQ:EIGR)

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced it would focus its development efforts on advancing avexitide in  ....

David Apelian , Eiger Biopharmaceuticals , Based Regimens , Peginterferon Lambda ,